- Conditions
- Advanced Head and Neck Squamous Cell Carcinoma
- Interventions
- CDX-3379 and cetuximab
- Drug
- Lead sponsor
- Celldex Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 10
- States / cities
- Tucson, Arizona • New Haven, Connecticut • Atlanta, Georgia + 7 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 817–840
of 3,760
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Head and Neck Squamous Cell Carcinoma (HNSCC)
- Interventions
- Semi-allogenic human fibroblast (MRC-5) transfected with DNA
- Biological
- Lead sponsor
- Robert Ferris
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2028
- U.S. locations
- 3
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Ductal Carcinoma, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer, Other Solid Tumors
- Interventions
- JAB-3312
- Drug
- Lead sponsor
- Jacobio Pharmaceuticals Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 4
- States / cities
- Denver, Colorado • Nashville, Tennessee • Houston, Texas + 1 more
- Conditions
- Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Breast Cancer, Colorectal Cancer, Melanoma, Bladder Cancer, Ovarian Cancer, Endometrial Cancer, Merkel Cell Carcinoma, GastroEsophageal Cancer, Renal Cell Carcinoma, Castration-resistant Prostate Cancer
- Interventions
- Etrumadenant, Zimberelimab
- Drug
- Lead sponsor
- Arcus Biosciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 12
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Denver, Colorado + 8 more
- Conditions
- Hiv, Hpv
- Interventions
- Self-Collection HPV testing kit from Abbott
- Diagnostic Test
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 21 Years to 40 Years · Female only
- Enrollment
- 650 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 9
- States / cities
- Denver, Colorado • Miami, Florida • Chicago, Illinois + 5 more
- Conditions
- Advanced Solid Tumors, Non-Small Cell Lung Cancer, Triple Negative Breast Cancer (TNBC), Colorectal Cancer, Head and Neck Squamous Cell Carcinoma, Metastatic Solid Tumors, Unresectable Solid Tumor
- Interventions
- IOV-5001
- Biological
- Lead sponsor
- Iovance Biotherapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2044
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Head and Neck Squamous Cell Carcinoma (HNSCC)
- Interventions
- Ulevostinag, Pembrolizumab
- Drug · Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 6
- States / cities
- Los Angeles, California • San Francisco, California • Detroit, Michigan + 3 more
- Conditions
- Pancreatic Ductal Adenocarcinoma, Gastric Cancer, Esophageal Cancer, Colorectal Cancer, Ovarian Cancer, Head and Neck Cancer, Sarcoma, Mesothelioma
- Interventions
- [203Pb]Pb-PSV359, [212Pb]Pb-PSV359
- Drug
- Lead sponsor
- Perspective Therapeutics
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 16
- States / cities
- Los Angeles, California • Miami, Florida • Kansas City, Kansas + 11 more
- Conditions
- Differentiated Thyroid Cancer
- Interventions
- Lenvatinib
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years and older
- Timeline
- Ends 2015
- U.S. locations
- 13
- States / cities
- La Jolla, California • Stanford, California • Torrance, California + 10 more
- Conditions
- Low-grade Oral Dysplasia
- Interventions
- Probiotic oral lozenges, Standard of care for oral dysplasia
- Biological · Other
- Lead sponsor
- Boston Medical Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Thyroid Nodule, Follicular Neoplasm
- Interventions
- Shear-Wave Elastography
- Device
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Hpv, HPV 16 Infection, HPV Infection, High Risk HPV
- Interventions
- Teal Wand Self-Collection Device Group
- Device
- Lead sponsor
- Teal Health, Inc.
- Industry
- Eligibility
- 25 Years to 65 Years · Female only
- Enrollment
- 870 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2027
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • San Francisco, California • Aurora, Colorado + 10 more
- Conditions
- Leydig Cell Tumor, Ovarian Sarcoma, Ovarian Stromal Cancer, Pseudomyxoma Peritonei, Recurrent Cervical Cancer, Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor, Recurrent Primary Peritoneal Cavity Cancer, Recurrent Uterine Sarcoma, Recurrent Vaginal Cancer, Recurrent Vulvar Cancer
- Interventions
- stereotactic body radiation therapy, carboplatin, gemcitabine hydrochloride, laboratory biomarker analysis, pharmacogenomic studies
- Radiation · Drug · Other
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 19 Years and older · Female only
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Squamous Cell Carcinoma of the Head and Neck
- Interventions
- Olaparib, Cetuximab, Radiation Therapy
- Drug · Radiation
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 1
- States / cities
- Denver, Colorado
- Conditions
- Head and Neck Squamous Cell Carcinoma (HNSCC)
- Interventions
- Nivolumab, Stereotactic Body Radiation Therapy (SBRT)
- Drug · Radiation
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 6
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 3 more
- Conditions
- Head and Neck Cancer
- Interventions
- Cohort 1 Not Previously Treated, Cohort 2 Treated Previously
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Squamous Cell Carcinoma, Pharyngocutaneous Fistula
- Interventions
- Removal of pharyngeal mucosa with decreased perfusion will be performed, SPY-PHI, ICG (Indocyanine Green)
- Procedure · Device · Drug
- Lead sponsor
- Matthew Spector
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 225 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Small Cell Carcinoma, Cervical Squamous Cell Carcinoma, Stage IB Cervical Cancer, Stage IIA Cervical Cancer, Stage IIB Cervical Cancer, Stage III Cervical Cancer, Stage IVA Cervical Cancer
- Interventions
- Gemcitabine Hydrochloride, Cisplatin, Radiation Therapy, Internal Radiation Therapy
- Drug · Radiation
- Lead sponsor
- Gynecologic Oncology Group
- Network
- Eligibility
- Female only
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2003
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Cervical Cancer
- Interventions
- Pembrolizumab, Paclitaxel, Cisplatin, Carboplatin, Bevacizumab, Placebo to pembrolizumab
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 617 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 20
- States / cities
- Anchorage, Alaska • Phoenix, Arizona • Orange, California + 15 more
- Conditions
- Carcinoma of the Head and Neck
- Interventions
- Talimogene Laherparepvec, Pembrolizumab
- Drug · Biological
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 8
- States / cities
- Newark, Delaware • Chicago, Illinois • Louisville, Kentucky + 3 more
- Conditions
- Xerostomia
- Interventions
- sugar-free chewing gum, chewing gum, mouth rinse, mouth spray
- Other · Drug
- Lead sponsor
- University of Oklahoma
- Other
- Eligibility
- 13 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2010
- U.S. locations
- 1
- States / cities
- Oklahoma City, Oklahoma
- Conditions
- Head and Neck Cancer, Squamous Cell Carcinoma of Head and Neck
- Interventions
- Cetuximab, Imatinib
- Drug
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Barrett Esophagus, Esophageal Cancer
- Interventions
- EnteroTracker
- Device
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 45 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2029
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Lung Cancer, Head and Neck Cancer
- Interventions
- Fresh tissue biopsy, Blood/Urine Sample Collection
- Other
- Lead sponsor
- University of Arkansas
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 330 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2028
- U.S. locations
- 1
- States / cities
- Little Rock, Arkansas